Montelukast Aurobindo (Montelukast)

Montelukast works by selectively blocking the cysteinyl leukotriene receptor CysLT1. This inhibition prevents leukotrienes from binding to the receptor, thereby reducing bronchoconstriction, mucus production, vascular leakage and inflammatory cell recruitment that contribute to asthma and allergic airway disease.

The dose of Montelukast Aurobindo is determined by the prescribing healthcare professional based on the patient’s age, weight, indication and clinical response. Dosage regimens are individualized and should follow the prescriber’s instructions.

Safety data for Montelukast in pregnancy are limited, and the product is classified as pregnancy category unknown. It should only be used if the potential benefit justifies any potential risk to the fetus. Caution is also advised during breastfeeding, and a clinician should evaluate the risk‑benefit ratio.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is particularly useful for patients with allergic components, exercise‑induced bronchoconstriction, or those who prefer a once‑daily oral tablet, but it is not a rescue bronchodilator.

Montelukast Aurobindo should be stored at ambient temperature below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Montelukast Aurobindo is taken orally, usually as a tablet, once daily in the evening. The tablet should be swallowed whole with water and not crushed or chewed unless otherwise directed by a healthcare professional.

Serious risks, though rare, include severe allergic reactions such as rash, angioedema or anaphylaxis, and neuropsychiatric events like depression, mood swings or suicidal thoughts. Patients should seek immediate medical attention if they experience any of these symptoms.

Montelukast Aurobindo should be avoided in individuals with a known hypersensitivity to montelukast or any of its excipients. It is also not recommended for patients who require immediate relief of acute bronchospasm, as it does not act as a rescue medication.